Navigation Links
Omeros Announces Positive OMS721 Data in Model of Thrombotic Microangiopathy
Date:4/2/2013

aging technique that allows direct visualization of dynamic biological processes in the microcirculation in live animals, the effects of OMS721 on thrombus formation were assessed. Specifically, the study evaluated OMS721's ability to delay the time to onset of thrombus formation and to complete occlusion of the blood vessel. 100 percent of isotype-antibody control animals versus 71 percent of OMS721-treated animals showed thrombus formation, with the initiation of thrombus formation delayed approximately three-fold in the OMS721-treated group relative to control (a median of 19.0 vs. 6.8 minutes; p=0.0097). Eighty percent of control-treated animals showed complete occlusion within the observation period while only 43 percent of those treated with OMS721 occluded completely. Median time to complete occlusion was 18.0 minutes for control and 38.0 minutes for the OMS721-treated animals (p=0.0036).

"These data are impressive," stated Markus Sperandio , M.D., professor of cardiovascular physiology and microvascular disorders at the Walter-Brendel-Center of Experimental Medicine, Munich, Germany, where he conducted the TMA studies evaluating OMS721. "OMS721 looks like a promising agent to prevent thrombus formation in the microcirculation.  We are planning additional studies to refine the dosing and timing of administration of OMS721 in models across a wide range of thrombotic disorders."

"We are pleased with these results and are excited to initiate the clinical program for OMS721," stated Gregory A. Demopulos , M.D., chairman and chief executive officer of Omeros. "The current treatment options for aHUS are limited and, when compared to those options, we believe that OMS721 carries marked advantages that will translate to significant patient benefits.  We are eager to evaluate the drug product in aHUS patients, and we remain on track to begin Phase 1 clinical t
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Omeros to Present at Deutsche Bank Securities Health Care Conference
2. Omeros Adds Four More Unlocked Orphan GPCRs to its Portfolio
3. Omeros to Present at Jefferies 2012 Global Healthcare Conference
4. Omeros Announces Proposed Public Offering of Common Stock
5. Omeros Prices $30 Million Public Offering of Common Stock
6. Omeros Announces Closing of $34.5 Million Public Offering of Common Stock
7. Omeros Successfully Completes Preclinical Studies of OMS824 for Schizophrenia and Phase 1 Clinical Trial Preparations Underway
8. Omeros Announces Discovery in MASP-2 Program
9. Omeros Corporation Reports Second Quarter 2012 Financial Results
10. Omeros Announces Completion of Enrollment in OMS103HP Phase 3 Clinical Trial
11. Omeros to Present at Two Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014 /CNW/ - On Aug. 20, ... , the Canadian Medical Association (CMA) voted on and ... plant material, including medicinal cannabis. Bedrocan Cannabis Corp., a ... of the CMA motion. The CMA is ... hazards associated with smoking any plant material, including medicinal ...
(Date:8/22/2014)... COLUMBUS, Ohio , Aug. 22, 2014 MC ... Devices Inc. (MID), a Columbus, OH ... to distribute the FloShield laparoscopic and robotic visualization system in ... will be approved for sale in Japan ... has a long-time experience and an extensive product portfolio in ...
(Date:8/22/2014)... Research and Markets has announced ... Respirators Industry Report 2014" report to their offering. ... Industry Report 2014 is a professional and in-depth study ... industry with a focus on the Chinese situation. ... including definitions, classifications, applications and industry chain structure. The ...
Breaking Medicine Technology:Bedrocan Canada Statement Regarding Canadian Medical Association Motion on Smoking Marijuana 2MC Medical agrees to be the exclusive distributor of FloShield products in Japan 2Global and Chinese Particulate Respirators Industry Report 2014 2
... 2011 Quest Diagnostics Incorporated (NYSE: DGX ... and services, announced that it is scheduled to speak ... York City. The presentation is scheduled for Tuesday, September ... The presentation will be webcast live during the conference ...
... Sept. 8, 2011 Spherix Incorporated ... in biotechnology for therapy in diabetes, metabolic syndrome ... consulting services to food, supplement, biotechnology and pharmaceutical ... SPX-106, achieved statistically significant reductions in VLDL and ...
Cached Medicine Technology:SPX-106T Treatment Yields Significant Reductions in Serum VLDL and LDL Cholesterol in Mice 2SPX-106T Treatment Yields Significant Reductions in Serum VLDL and LDL Cholesterol in Mice 3
(Date:8/23/2014)... (PRWEB) August 23, 2014 Having been in ... dental hygienist from Arlington, Texas, saw a need for an ... toothpaste. "That’s when I came up with the idea for ... provides an effective way for a user to clean the ... to carry multiple items. It also helps avoid plaque buildup ...
(Date:8/23/2014)... (PRWEB) August 23, 2014 Hundreds ... filed on behalf of individuals who were allegedly ... replacement line continue to move forward in the ... Liebhard LLP reports. According to an Order dated ... trial program that would allow the litigation’s first ...
(Date:8/23/2014)... GBI Research, the leading business intelligence ... in Major Developed Markets to 2020 - New and ... which provides in-depth analysis of the critical care market ... and Canada. The report provides an estimation of market ... It covers critical care indications that are being treated ...
(Date:8/23/2014)... Pixel Film Studios, a leader of Final Cut ... ProIntro Vol.3, a customizable title tool for FCPX ... by dragging ProIntro Vol.3 in their timeline" says Christina Austin, ... time saver and i think our users will agree" , ... titles made with Final Cut Pro X users in mind. ...
(Date:8/23/2014)... Youth substance abuse is a serious problem across ... TX. Substance abuse can happen to people of all ... dependency in higher numbers than ever before. Many ... don’t know where to find professional youth rehab. ... because most treatment options are designed for adults. The ...
Breaking Medicine News(10 mins):Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 2Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 3Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 4Health News:Critical Care Therapeutics in Major Developed Markets to 2020 | Researchmoz 2Health News:Critical Care Therapeutics in Major Developed Markets to 2020 | Researchmoz 3Health News:A new plugin was announced today, ProIntro Vol.3 from Pixel Film Studios for Final Cut Pro X 2Health News:New Houston Hotline Assisting Juveniles in Locating Dependable Rehabilitation Help 2
... Md., May 8 Micromet, Inc. (Nasdaq:,MITI), a biopharmaceutical ... the treatment of cancer, inflammation and,autoimmune diseases, today announced ... 2008., Summary of Recent Events:, -- ... phase 1 clinical trial with ...
... Sciences,Inc. (Nasdaq: HGSI ) today announced that John ... of Pfizer Global Research and,Development, has been appointed to ... ), "We are honored to have John ... President and Chief Executive Officer, HGS. "John,s,record of accomplishment ...
... Ortho Organizers, Inc., a,leading manufacturer of orthodontic ... of their new premium O2 Select Orthodontic,Instruments., ... Organizers President and CEO George W. Guttroff ... with the release of O2 Select,Orthodontic Instruments. ...
... than $8 million for medicines and other lifesaving ... ... death toll from,Cyclone Nargis climbs steeply, UNICEF is gravely concerned that the ... increase the death toll among children and other,vulnerable populations, leading to a ...
... Calif., May 8 Samplify Systems, Inc., a,real-time ... Crawford, a leading expert in computed tomography, has ... of experience in the,architecture, design, and development of ... "We are delighted to add Carl,s knowledge of ...
... Hospital buildings can heal,according to the first ... the,physical environment on child patients in health care ... through the,Physical Environment is produced by the National ... partnership with the Center,for Health Design. Findings from ...
Cached Medicine News:Health News:Micromet, Inc. Reports First Quarter 2008 Financial Results 2Health News:Micromet, Inc. Reports First Quarter 2008 Financial Results 3Health News:Micromet, Inc. Reports First Quarter 2008 Financial Results 4Health News:Micromet, Inc. Reports First Quarter 2008 Financial Results 5Health News:Micromet, Inc. Reports First Quarter 2008 Financial Results 6Health News:Micromet, Inc. Reports First Quarter 2008 Financial Results 7Health News:Micromet, Inc. Reports First Quarter 2008 Financial Results 8Health News:Micromet, Inc. Reports First Quarter 2008 Financial Results 9Health News:Human Genome Sciences Appoints John L. Lamattina, Ph.D., to Its Board of Directors 2Health News:Human Genome Sciences Appoints John L. Lamattina, Ph.D., to Its Board of Directors 3Health News:Human Genome Sciences Appoints John L. Lamattina, Ph.D., to Its Board of Directors 4Health News:Ortho Organizers(R) Introduces New Premium Product Line - O2 Select(TM) Orthodontic Instruments 2Health News:Myanmar Cyclone a Children's Catastrophe - UNICEF 2Health News:Samplify Systems Adds Computed Tomography Expert Carl Crawford to Technical Team 2Health News:Hospital Buildings Can Heal According to First Comprehensive Report on Impact of Physical Environment on Child Patients 2Health News:Hospital Buildings Can Heal According to First Comprehensive Report on Impact of Physical Environment on Child Patients 3Health News:Hospital Buildings Can Heal According to First Comprehensive Report on Impact of Physical Environment on Child Patients 4
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Medicine Products: